Does the media favor CTKB or ALMR?

In the previous week, Cytek Biosciences had 2 more articles in the media than Alamar Biosciences. MarketBeat recorded 4 mentions for Cytek Biosciences and 2 mentions for Alamar Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat Alamar Biosciences' score of 0.62 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRVI or CTKB?

In the previous week, Maravai LifeSciences had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 6 mentions for Maravai LifeSciences and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat Maravai LifeSciences' score of 0.45 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CTKB or BLFS?

In the previous week, BioLife Solutions had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for BioLife Solutions and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat BioLife Solutions' score of 1.01 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PSNL or CTKB?

In the previous week, Personalis had 5 more articles in the media than Cytek Biosciences. MarketBeat recorded 9 mentions for Personalis and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat Personalis' score of 0.38 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FTRE or CTKB?

In the previous week, Fortrea had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for Fortrea and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat Fortrea's score of 0.66 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytek Biosciences (CTKB) Competitors

$4.68 +0.06 (+1.30%)

As of 08/28/2026 04:00 PM Eastern

Compare

CTKB vs. ALMR, MRVI, BLFS, PSNL, and FTRE

Should you buy Cytek Biosciences stock or one of its competitors? Cytek Biosciences's main competitors and comparable companies include Alamar Biosciences (ALMR), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), Personalis (PSNL), and Fortrea (FTRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Cytek Biosciences compare to Alamar Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Alamar Biosciences has a net margin of 0.00% compared to Cytek Biosciences' net margin of -38.98%. Alamar Biosciences' return on equity of 0.00% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Alamar Biosciences	N/A	N/A	N/A

Cytek Biosciences currently has a consensus target price of $5.56, suggesting a potential upside of 18.86%. Alamar Biosciences has a consensus target price of $31.80, suggesting a potential upside of 3.55%. Given Cytek Biosciences' higher probable upside, equities research analysts clearly believe Cytek Biosciences is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Alamar Biosciences has lower revenue, but higher earnings than Cytek Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.02	-$66.54M	-$0.62	N/A
Alamar Biosciences	$100.42M	21.22	-$29.82M	-$1.96	N/A

69.5% of Cytek Biosciences shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cytek Biosciences had 2 more articles in the media than Alamar Biosciences. MarketBeat recorded 4 mentions for Cytek Biosciences and 2 mentions for Alamar Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat Alamar Biosciences' score of 0.62 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cytek Biosciences beats Alamar Biosciences on 8 of the 15 factors compared between the two stocks.

How does Cytek Biosciences compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Cytek Biosciences has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$208.78M	9.55	-$130.77M	-$0.52	N/A
Cytek Biosciences	$201.49M	3.02	-$66.54M	-$0.62	N/A

Maravai LifeSciences has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Maravai LifeSciences has a net margin of -37.07% compared to Cytek Biosciences' net margin of -38.98%. Cytek Biosciences' return on equity of -12.40% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Maravai LifeSciences had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 6 mentions for Maravai LifeSciences and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat Maravai LifeSciences' score of 0.45 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences presently has a consensus target price of $6.25, suggesting a potential downside of 18.62%. Cytek Biosciences has a consensus target price of $5.56, suggesting a potential upside of 18.86%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cytek Biosciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Cytek Biosciences beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to BioLife Solutions?

Cytek Biosciences (NASDAQ:CTKB) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Cytek Biosciences has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

BioLife Solutions has a net margin of 53.29% compared to Cytek Biosciences' net margin of -38.98%. BioLife Solutions' return on equity of 2.70% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
BioLife Solutions	53.29%	2.70%	2.49%

BioLife Solutions has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.02	-$66.54M	-$0.62	N/A
BioLife Solutions	$96.21M	18.48	-$4.59M	$1.16	31.36

Cytek Biosciences presently has a consensus price target of $5.56, suggesting a potential upside of 18.86%. BioLife Solutions has a consensus price target of $31.38, suggesting a potential downside of 13.76%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cytek Biosciences is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18

In the previous week, BioLife Solutions had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for BioLife Solutions and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat BioLife Solutions' score of 1.01 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BioLife Solutions beats Cytek Biosciences on 11 of the 17 factors compared between the two stocks.

How does Cytek Biosciences compare to Personalis?

Personalis (NASDAQ:PSNL) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Personalis had 5 more articles in the media than Cytek Biosciences. MarketBeat recorded 9 mentions for Personalis and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat Personalis' score of 0.38 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Personalis has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

61.9% of Personalis shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 4.2% of Personalis shares are held by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cytek Biosciences has a net margin of -38.98% compared to Personalis' net margin of -153.84%. Cytek Biosciences' return on equity of -12.40% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

Cytek Biosciences has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67M	25.66	-$81.27M	-$1.09	N/A
Cytek Biosciences	$201.49M	3.02	-$66.54M	-$0.62	N/A

Personalis currently has a consensus price target of $14.54, suggesting a potential downside of 14.85%. Cytek Biosciences has a consensus price target of $5.56, suggesting a potential upside of 18.86%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Cytek Biosciences beats Personalis on 12 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Fortrea presently has a consensus price target of $20.75, indicating a potential upside of 10.31%. Cytek Biosciences has a consensus price target of $5.56, indicating a potential upside of 18.86%. Given Cytek Biosciences' higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

69.5% of Cytek Biosciences shares are owned by institutional investors. 0.7% of Fortrea shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Fortrea had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for Fortrea and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.27 beat Fortrea's score of 0.66 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.67	-$986.20M	-$0.91	N/A
Cytek Biosciences	$201.49M	3.02	-$66.54M	-$0.62	N/A

Fortrea has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Fortrea has a net margin of -3.18% compared to Cytek Biosciences' net margin of -38.98%. Fortrea's return on equity of 10.72% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

Summary

Cytek Biosciences beats Fortrea on 8 of the 15 factors compared between the two stocks.

Get Cytek Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTKB vs. The Competition

Export

Metric	Cytek Biosciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$608.32M	$10.11B	$7.20B	$12.90B
Dividend Yield	N/A	1.46%	2.54%	11.28%
P/E Ratio	-7.55	62.76	273.16	25.45
Price / Sales	3.02	111.63	605.01	76.63
Price / Cash	N/A	26.70	76.74	53.00
Price / Book	1.89	37.29	12.98	6.14
Net Income	-$66.54M	$56.67B	$3.48B	$348.86M
7 Day Performance	-2.70%	-1.52%	0.13%	-0.80%
1 Month Performance	8.58%	7.21%	7.08%	4.13%
1 Year Performance	13.04%	24.31%	24.67%	15.17%

Cytek Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTKB Cytek Biosciences	2.1812 of 5 stars	$4.68 +1.3%	$5.56 +18.9%	+13.0%	$608.32M	$201.49M	N/A	500
ALMR Alamar Biosciences	1.8223 of 5 stars	$33.02 +1.0%	$31.80 -3.7%	N/A	$2.27B	$74.21M	N/A	222
MRVI Maravai LifeSciences	1.3175 of 5 stars	$9.00 +6.8%	$6.25 -30.6%	+217.4%	$2.19B	$185.74M	N/A	610	News Coverage Analyst Forecast Gap Down
BLFS BioLife Solutions	2.9162 of 5 stars	$37.22 +0.1%	$31.38 -15.7%	+45.2%	$1.82B	$96.21M	32.09	440	Positive News High Trading Volume
PSNL Personalis	1.5804 of 5 stars	$17.25 +1.1%	$14.54 -15.7%	+249.1%	$1.79B	$69.65M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTKB) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, MRVI, BLFS, PSNL, and FTRE

How does Cytek Biosciences compare to Alamar Biosciences?

Summary

How does Cytek Biosciences compare to Maravai LifeSciences?

Summary

How does Cytek Biosciences compare to BioLife Solutions?

Summary

How does Cytek Biosciences compare to Personalis?

Summary

How does Cytek Biosciences compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, MRVI, BLFS, PSNL, and FTRE

How does Cytek Biosciences compare to Alamar Biosciences?

Is CTKB or ALMR more profitable?

Do analysts rate CTKB or ALMR?

Which has preferable valuation & earnings, CTKB or ALMR?

Do institutionals & insiders hold more shares of CTKB or ALMR?

Does the media favor CTKB or ALMR?

Summary

How does Cytek Biosciences compare to Maravai LifeSciences?

Which has preferable valuation & earnings, MRVI or CTKB?

Which has more risk and volatility, MRVI or CTKB?

Is MRVI or CTKB more profitable?

Do institutionals & insiders have more ownership in MRVI or CTKB?

Does the media prefer MRVI or CTKB?

Do analysts prefer MRVI or CTKB?

Summary

How does Cytek Biosciences compare to BioLife Solutions?

Which has more risk & volatility, CTKB or BLFS?

Is CTKB or BLFS more profitable?

Which has preferable valuation & earnings, CTKB or BLFS?

Do analysts prefer CTKB or BLFS?

Does the media prefer CTKB or BLFS?

Do insiders & institutionals hold more shares of CTKB or BLFS?

Summary

How does Cytek Biosciences compare to Personalis?

Does the media refer more to PSNL or CTKB?

Which has more volatility and risk, PSNL or CTKB?

Do institutionals & insiders believe in PSNL or CTKB?

Is PSNL or CTKB more profitable?

Which has preferable earnings & valuation, PSNL or CTKB?

Do analysts prefer PSNL or CTKB?

Summary

How does Cytek Biosciences compare to Fortrea?

Do analysts prefer FTRE or CTKB?

Do insiders and institutionals believe in FTRE or CTKB?

Does the media refer more to FTRE or CTKB?

Which has better earnings and valuation, FTRE or CTKB?

Which has more volatility & risk, FTRE or CTKB?

Is FTRE or CTKB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools